Forbes: 라임병 백신은 4~5년 안에 준비될 수 있습니다.
Forbes: 라임병 백신은 4~5년 안에 준비될 수 있습니다.
YouTube video highlight
Lyme Disease Vaccine Could Be Ready In 4 to 5 Years
Read more about the projectForbes: 라임병 백신은 4~5년 안에 준비될 수 있습니다.
Lyme Disease Vaccine Could Be Ready In 4 to 5 Years
Lyme disease is one of the fastest growing diseases in the northern hemisphere and this week’s announcement that pop star Justin Beiber had the diagnosis brought the tick-borne illness to the forefront of the news. For now, the main prevention lies in avoiding tick contact but one company, Valneva, is working fervently to develop what they believe will be the world’s first vaccine against Lyme’s disease.
Valneva’s has made a name for itself by developing vaccines for in-demand illnesses and now the biotech company has its eyes set on Lyme disease. Their Lyme disease vaccine prototype, VLA15 is currently in Phase 2 developments and is being tested on more than 800 people to measure both efficacy and safety. Although difficult to predict, Valneva’s CEO, Thomas Lingelbach told Forbes that he expected the vaccine to be completed in the next few years.
“Phase 2 will end in the middle of 2020. We expect this will enable us to enter the last clinical phase in mid-2021,” explained Lingelbach. “Depending on those results, we may be four to four and a half years away from the first potential Lyme disease vaccine.”
When completed, the vaccine will likely be administered in three doses, each a month apart. The initial vaccine is expected to last 6 seasons, referring to the time from spring to late summer when the ticks are active and therefore most likely to transfer the illness to humans. After six seasons, Lingelbach believes that boosters will be required, but will likely be needed to be administered every 2-3 seasons.
Read the full article by Dana Dovey on Forbes' website here.
Lyme Disease Vaccine Could Be Ready In 4 to 5 Years
Lyme disease is one of the fastest growing diseases in the northern hemisphere and this week’s announcement that pop star Justin Beiber had the diagnosis brought the tick-borne illness to the forefront of the news. For now, the main prevention lies in avoiding tick contact but one company, Valneva, is working fervently to develop what they believe will be the world’s first vaccine against Lyme’s disease.
Valneva’s has made a name for itself by developing vaccines for in-demand illnesses and now the biotech company has its eyes set on Lyme disease. Their Lyme disease vaccine prototype, VLA15 is currently in Phase 2 developments and is being tested on more than 800 people to measure both efficacy and safety. Although difficult to predict, Valneva’s CEO, Thomas Lingelbach told Forbes that he expected the vaccine to be completed in the next few years.
“Phase 2 will end in the middle of 2020. We expect this will enable us to enter the last clinical phase in mid-2021,” explained Lingelbach. “Depending on those results, we may be four to four and a half years away from the first potential Lyme disease vaccine.”
When completed, the vaccine will likely be administered in three doses, each a month apart. The initial vaccine is expected to last 6 seasons, referring to the time from spring to late summer when the ticks are active and therefore most likely to transfer the illness to humans. After six seasons, Lingelbach believes that boosters will be required, but will likely be needed to be administered every 2-3 seasons.
Read the full article by Dana Dovey on Forbes' website here.
Lyme Disease Vaccine Could Be Ready In 4 to 5 Years
Lyme disease is one of the fastest growing diseases in the northern hemisphere and this week’s announcement that pop star Justin Beiber had the diagnosis brought the tick-borne illness to the forefront of the news. For now, the main prevention lies in avoiding tick contact but one company, Valneva, is working fervently to develop what they believe will be the world’s first vaccine against Lyme’s disease.
Valneva’s has made a name for itself by developing vaccines for in-demand illnesses and now the biotech company has its eyes set on Lyme disease. Their Lyme disease vaccine prototype, VLA15 is currently in Phase 2 developments and is being tested on more than 800 people to measure both efficacy and safety. Although difficult to predict, Valneva’s CEO, Thomas Lingelbach told Forbes that he expected the vaccine to be completed in the next few years.
“Phase 2 will end in the middle of 2020. We expect this will enable us to enter the last clinical phase in mid-2021,” explained Lingelbach. “Depending on those results, we may be four to four and a half years away from the first potential Lyme disease vaccine.”
When completed, the vaccine will likely be administered in three doses, each a month apart. The initial vaccine is expected to last 6 seasons, referring to the time from spring to late summer when the ticks are active and therefore most likely to transfer the illness to humans. After six seasons, Lingelbach believes that boosters will be required, but will likely be needed to be administered every 2-3 seasons.
Read the full article by Dana Dovey on Forbes' website here.
Recent articles
Other categories
You might also like
미디어 언급
An investment helps provide years of safe drinking water for entire families and schools.
미디어 언급
You spray [permethrin] on your clothes and gear and it turns them into a barrier bugs don't want to cross.
미디어 언급
The Smartwater bottle’s small opening allows you to screw on filters, such as those from Sawyer.
Built for the Outdoors
see ALL PRODUCTS
인스타그램 팔로우하기
아웃도어 기업 그 이상.
From the trail
라파 홍보대사를 만나보세요. 이들은 트레일 전문가로서 험난한 환경에 견디는 데카트론 제품을 사랑하고, 한 차원 높은 모험 이야기를 통해 데카트론을 즐겁게 해줍니다.
meet our ambassadors
